2. Search Result
Search Result
Results for "

Serum cholesterol

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

8

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-21196A
    Potassium perfluorohexanesulfonate

    		Phosphatase Metabolic Disease
    Potassium perfluorohexanesulfonate is an orally active surfactant found in sera of the general population. Potassium perfluorohexanesulfonate induces adaptive hepatocellular hypertrophy, decreases serum cholesterol and increases alkaline phosphatase in male mice .
    Potassium perfluorohexanesulfonate
  • HY-W012946
    2-Furoic acid

    Pyromucic acid

    		 ATP Citrate Lyase Acyltransferase Endogenous Metabolite Metabolic Disease
    2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
    2-Furoic acid
  • HY-113486S
    (S)-Lathosterol-d4

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    (S)-Lathosterol-d4 is the deuterium labeled (S)-Lathosterol. Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis .
    (S)-Lathosterol-d4
  • HY-101812
    Terbufibrol

    		Others Metabolic Disease
    Terbufibrol has been shown highly active in reducing serum total cholesterol (TC) levels in the normal and hypercholesterolemic male rat.
    Terbufibrol
  • HY-113288
    Campestanol

    		LDLR Metabolic Disease
    Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders .
    Campestanol
  • HY-W012946S
    2-Furoic acid-d3

    		Acyltransferase ATP Citrate Lyase Endogenous Metabolite Metabolic Disease
    2-Furoic acid-d3 is the deuterium labeled 2-Furoic acid . 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
    2-Furoic acid-d3
  • HY-176560
    Raloxifene alkene

    		Others Metabolic Disease Cancer
    Raloxifene alkene (Compound 101) is a serum cholesterol clearance agent. Raloxifene alkene has significant anti-proliferation activity against breast adenocarcinoma cells. Raloxifene alkene effectively reduces serum cholesterol level without significant uterine weight and increase of number oieosinoohils in the stromallaver of ovarleclomized rat models. Raloxifene alkene can be used for post-menopausasyndrome, particularly osteoporosis, estrogen-dependent breast and uterine carcinoma research .
    Raloxifene alkene
  • HY-111983
    Etiroxate

    CG-635

    		 Thyroid Hormone Receptor Drug Derivative Metabolic Disease
    Etiroxate (CG-635) is a lipid lowing compound which can be used for hyperlipoproteinemia research .
    Etiroxate
  • HY-121413
    Clinolamide

    		Endogenous Metabolite Others
    Clinolamide is an N-cyclohexyl linoleamide. In a rat cholesterol metabolism study, feeding it at a dose of 0.3% for 21 days had no significant effect on serum, liver or kidney cholesterol levels, but had different effects on cholesterol synthesis in liver slices under different substrates and concentrations.
    Clinolamide
  • HY-114952
    SM-32504

    		Acyltransferase Cardiovascular Disease
    SM-32504 is an effective ACAT inhibitor that can significantly reduce serum cholesterol levels in mouse models fed with high-fat and high-cholesterol diets. SM-32504 can be used for research on hypercholesterolemia and atherosclerosis .
    SM-32504
  • HY-B1189S
    Meglutol-d3

    Dicrotalic acid-d3; 3-Hydroxy-3-methylglutaric acid-d3

    		 Autophagy HMG-CoA Reductase (HMGCR) Endogenous Metabolite Cardiovascular Disease
    Meglutol-d3 is the deuterium labeled Meglutol . Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.
    Meglutol-d3
  • HY-W012946R
    2-Furoic acid (Standard)

    Pyromucic acid (Standard)

    		 Reference Standards ATP Citrate Lyase Acyltransferase Endogenous Metabolite Metabolic Disease
    2-Furoic acid (Standard) is the analytical standard of 2-Furoic acid. This product is intended for research and analytical applications. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
    2-Furoic acid (Standard)
  • HY-113526
    AR-12463

    		Drug Derivative Endogenous Metabolite Cardiovascular Disease
    AR-12463 is a derivative of Trapidil (HY-B1016). AR-12463 inhibits the conversion of [14C]acetate to cholesterol. AR-12463 significantly reduces the elevation of total cholesterol in rabbit serum and prevents cholesterol incorporation into tissues. AR-12463 can be used to study atherosclerosis.
    AR-12463
  • HY-13556A
    Arzoxifene hydrochloride
    1 Publications Verification

    LY353381 hydrochloride; SERM III hydrochloride

    		 Estrogen Receptor/ERR Cancer
    Arzoxifene (LY353381) hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.
    Arzoxifene hydrochloride
  • HY-P3704
    Enterostatin (rat)

    		Endogenous Metabolite Metabolic Disease
    Enterostatin (rat), an orally active activation peptide of procolipase, selectively reduces fat intake. Enterostatin (rat) reduces serum cholesterol levels by way of a CCK1 receptor-dependent mechanism .
    Enterostatin (rat)
  • HY-114316
    HMG499

    		HMG-CoA Reductase (HMGCR) Autophagy Cardiovascular Disease Metabolic Disease
    HMG499 is a potent and selective HMG-CoA reductase inhibitor with an IC50 of 0.41 μM. HMG499 can prevent statins-induced accumulation of HMGCR, reduce serum cholesterol levels and decrease atherosclerosis .
    HMG499
  • HY-19852
    KRP-105

    		PPAR Metabolic Disease
    KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia .
    KRP-105
  • HY-B1189
    Meglutol

    Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid

    		 HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .
    Meglutol
  • HY-14998
    Halofenate

    MK 185

    		 β-catenin PPAR Wnt Endocrinology
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo .
    Halofenate
  • HY-119064
    L-645164

    		HMG-CoA Reductase (HMGCR) Neurological Disease
    L-645164 is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. L-645164 produces substantial decreases in circulating serum cholesterol concentrations in dogs. L-645164 is promising for research of central nervous system disorders .
    L-645164
  • HY-B1189R
    Meglutol (Standard)

    		HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Cardiovascular Disease Metabolic Disease
    Meglutol (Standard) is the analytical standard of Meglutol. This product is intended for research and analytical applications. Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .
    Meglutol (Standard)
  • HY-B0998
    Dehydrocholic acid sodium

    Dehydrocholate sodium

    		 Amylases Lipase Autophagy Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) sodium is an orally active hydrocholeretic agent. Dehydrocholic acid sodium modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid sodium has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid sodium can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid sodium
  • HY-B1393
    Dehydrocholic acid

    Dehydrocholate

    		 Autophagy Amylases Lipase Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid
  • HY-178015
    THR-β agonist 11

    		Thyroid Hormone Receptor Metabolic Disease Inflammation/Immunology
    THR-β agonist 11 is an orally active and selective thyroid hormone receptor (THR-β) agonist. THR-β agonist 11 shows potent cholesterol-lowering activity in cholesterol-fed rats. THR-β agonist 11 significantly reduces serum total TG, LDL-cholesterol, liver total TC and TG levels, and alleviates hepatic steatosis, inflammation and fibrosis in HFD-CCl4-induced Metabolic dysfunction-associated steatohepatitis (MASH) model mice. THR-β agonist 11 can be used for the study of metabolic dysfunction-associated steatohepatitis (MASH) and other fibrotic diseases .
    THR-β agonist 11
  • HY-W008581
    Estradiol 3-methyl ether

    3-O-Methyl estradiol; 17β-Estradiol 3-methyl ether; 3-Methoxyestradiol

    		 Biochemical Assay Reagents Endocrinology
    Estradiol 3-methyl ether is a synthetic estrogen. Estradiol 3-methyl ether can disrupt microtubule networks in V79 cells with an EC50 of 9 μM, as well as inhibiting cell proliferation. Estradiol 3-methyl ether decreases the serum cholesterol levels and increases body weight loss, which indicates feminizing activity in HFD murine model .
    Estradiol 3-methyl ether
  • HY-15790H
    (S)-Elobixibat

    (S)-A 3309; (S)-AZD 7806

    		 Apical Sodium-Dependent Bile Acid Transporter TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology
    (S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to treat metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors .
    (S)-Elobixibat
  • HY-119805
    YM 13650

    		Others Inflammation/Immunology
    YM 13650 is an orally active anti-nephritic agent. YM 13650 exhibits dose-dependent preventive and therapeutic effects in both the rat immune complex nephritis model and the mouse spontaneous lupus nephritis model. YM 13650 can inhibit the increase in urinary protein, improve serum cholesterol and urea nitrogen levels, alleviate renal pathological damage, and prolong the survival time of mice. YM 13650 can be used in the research of nephritic diseases .
    YM 13650
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-B1393R
    Dehydrocholic acid (Standard)

    Dehydrocholate (Standard)

    		 Reference Standards Autophagy Amylases Lipase Metabolic Disease
    Dehydrocholic acid (Dehydrocholate) (Standard) is the analytical standard of Dehydrocholic acid (HY-B1393). This product is intended for research and analytical applications. Dehydrocholic acid (Dehydrocholate) is an orally active hydrocholeretic agent. Dehydrocholic acid modulates Autophagy, reduces serum amylase and lipase levels. Dehydrocholic acid has the effects of promoting choleretic function, protecting the liver, reducing pancreatic damage, and regulating cholesterol metabolism. Dehydrocholic acid can be used in the study of acute biliary pancreatitis and obstructive jaundice .
    Dehydrocholic acid (Standard)
  • HY-172661
    Kylo-0603

    		Thyroid Hormone Receptor Interleukin Related LDLR Infection Metabolic Disease
    KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .
    Kylo-0603
  • HY-W009732
    Sinapinic acid
    5 Publications Verification

    Sinapic acid

    		 HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .
    Sinapinic acid
  • HY-15790
    Elobixibat

    A 3309; AZD 7806

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat (A 3309; AZD 7806) is an orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat
  • HY-W009732R
    Sinapinic acid (Standard)

    		HDAC Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM , and also inhibits ACE-I activity . Sinapinic acid posssess potent anti-tumor activity, induces apoptosis of tumor cells . Sinapinic acid shows antioxidant and antidiabetic activities . Sinapinic acid reduces total cholesterol, triglyceride, and HOMA-IR index, and also normalizes some serum parameters of antioxidative abilities and oxidative damage in ovariectomized rats .
    Sinapinic acid (Standard)
  • HY-15790A
    Elobixibat hydrate

    A 3309 hydrate; AZD 7806 hydrate

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Cancer
    Elobixibat (A 3309; AZD 7806) hydrate is an orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat hydrate can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat hydrate can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat hydrate
  • HY-19522C
    Seladelpar Lysine dihydrate
    1 Publications Verification

    MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate

    		 PPAR Metabolic Disease
    Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC50 of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .
    Seladelpar Lysine dihydrate
  • HY-15790S
    Elobixibat-d5

    A 3309-d5; AZD 7806-d5

    		 Isotope-Labeled Compounds Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790). Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat-d5
  • HY-15790R
    Elobixibat (Standard)

    A 3309 (Standard); AZD 7806 (Standard)

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease Inflammation/Immunology Cancer
    Elobixibat (Standard) is the analytical standard of Elobixibat (HY-15790). This product is intended for research and analytical applications. Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT). Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly .
    Elobixibat (Standard)
  • HY-15929
    TBHBA
    1 Publications Verification

    2,4,6-Tribromo-3-hydroxybenzoic acid

    		 Biochemical Assay Reagents Others
    TBHBA (2,4,6-Tribromo-3-hydroxybenzoic acid) is a chemical colorimetric agent and nanomaterial surface modifier. TBHBA can react with some oxidants (such as H2O2) to generate high-absorbance quinoneimine dyes, which enhance the sensitivity of HDL cholesterol enzymatic determination. TBHBA can be used as a bromine-containing coupling agent to modify the surface of silica nanoparticles through esterification reaction. Thereby, organic flame retardant groups are introduced to improve the thermal stability and flame retardant properties of nanocomposites. TBHBA can be used in clinical biochemical testing (such as serum lipoprotein analysis) and the preparation of flame-retardant polymer nanocomposites .
    TBHBA
  • HY-138089
    17β-Hydroxy exemestane

    		Androgen Receptor Estrogen Receptor/ERR LDLR Metabolic Disease Cancer
    17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .
    17β-Hydroxy exemestane

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: